Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Wu, Yuao; Vazquez-Prada, Karla X.; Liu, Yajun; Whittaker, Andrew K.; Zhang, Run; Ta, Hang T.

doi:10.7150/ntno.62730

Theranostics

International Journal of Biological Sciences

International Journal of Medical Sciences

Journal of Cancer

open access Global reach, higher impact

Full Text | PDF

Nanotheranostics 2021; 5(4):499-514. doi:10.7150/ntno.62730 This issue Cite

Research Paper

Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases

Yuao Wu^1,3, Karla X. Vazquez-Prada^1,3, Yajun Liu³, Andrew K. Whittaker^3,4, Run Zhang³, Hang T. Ta^1,2,3✉

1. Queensland Micro- and Nanotechnology, Griffith University, Brisbane, Queensland 4111, Australia
2. School of Environment and Science, Griffith University, Brisbane, Queensland 4111, Australia
3. Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, Brisbane, Queensland 4072, Australia
4. ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, the University of Queensland, QLD 4072, Australia

Citation:

Wu Y, Vazquez-Prada KX, Liu Y, Whittaker AK, Zhang R, Ta HT. Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Nanotheranostics 2021; 5(4):499-514. doi:10.7150/ntno.62730. https://www.ntno.org/v05p0499.htm

Other styles

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide. CVD includes a group of disorders of the heart and blood vessels such as myocardial infarction, ischemic heart, ischemic injury, injured arteries, thrombosis and atherosclerosis. Amongst these, atherosclerosis is the dominant cause of CVD and is an inflammatory disease of the blood vessel wall. Diagnosis and treatment of CVD remain the main challenge due to the complexity of their pathophysiology. To overcome the limitations of current treatment and diagnostic techniques, theranostic nanomaterials have emerged. The term "theranostic nanomaterials" refers to a multifunctional agent with both therapeutic and diagnostic abilities. Theranostic nanoparticles can provide imaging contrast for a diversity of techniques such as magnetic resonance imaging (MRI), positron emission tomography (PET) and computed tomography (CT). In addition, they can treat CVD using photothermal ablation and/or medication by the drugs in nanoparticles. This review discusses the latest advances in theranostic nanomaterials for the diagnosis and treatment of CVDs according to the order of disease development. MRI, CT, near-infrared spectroscopy (NIR), and fluorescence are the most widely used strategies on theranostics for CVDs detection. Different treatment methods for CVDs based on theranostic nanoparticles have also been discussed. Moreover, current problems of theranostic nanoparticles for CVDs detection and treatment and future research directions are proposed.

Keywords: theranostics, nanomaterials, cardiovascular diseases, atherosclerosis, thrombosis, myocardial infarction, ischemic heart

Citation styles

APA

Wu, Y., Vazquez-Prada, K.X., Liu, Y., Whittaker, A.K., Zhang, R., Ta, H.T. (2021). Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Nanotheranostics, 5(4), 499-514. https://doi.org/10.7150/ntno.62730.

ACS

Wu, Y.; Vazquez-Prada, K.X.; Liu, Y.; Whittaker, A.K.; Zhang, R.; Ta, H.T. Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Nanotheranostics 2021, 5 (4), 499-514. DOI: 10.7150/ntno.62730.

NLM

CSE

Wu Y, Vazquez-Prada KX, Liu Y, Whittaker AK, Zhang R, Ta HT. 2021. Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Nanotheranostics. 5(4):499-514.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.